Insights

Clinical leadership Leverage BrainsWay’s FDA-cleared Deep TMS platform with multiple indications (MDD, OCD, smoking cessation) to cross-sell into adjacent psychiatric and neurological treatment areas, highlighting proven efficacy and expanding adoption through ongoing trials.

Global expansion Target healthcare systems and distributors in regions prioritizing noninvasive neuromodulation; emphasize BrainsWay’s global footprint, strong clinical evidence base, and commitment to broad access to Deep TMS to accelerate market penetration.

Healthcare partnerships Position partnerships with hospitals, clinics, and payer networks around reimbursement expansion and SWIFT protocol adoption to drive increased utilization and more rapid patient access.

Financial momentum Capitalize on recent revenue growth and positive earnings outlook to attract strategic investors and channel partners, underscoring scalable deployments, growing installed base, and expanding market demand.

Tech-enabled selling Highlight BrainsWay’s technology stack and data capabilities (Tableau, HubSpot, Drupal, analytics) as a differentiator for enterprise customers seeking integrated, measurable outcomes and streamlined procurement and installation processes.

Similar companies to BrainsWay

BrainsWay Tech Stack

BrainsWay uses 8 technology products and services including Microsoft Advertising, HubSpot Analytics, Tableau, and more. Explore BrainsWay's tech stack below.

Media & News

BrainsWay's Email Address Formats

BrainsWay uses at least 4 email formats:
BrainsWay Email FormatsExamplePercentage
First.Last@brainsway.comJohn.Doe@brainsway.com
63%
First@brainsway.comJohn@brainsway.com
20%
FirstLast@brainsway.comJohnDoe@brainsway.com
9%
Last@brainsway.comDoe@brainsway.com
8%

Frequently Asked Questions

What is BrainsWay's stock symbol?

Minus sign iconPlus sign icon
BrainsWay is a publicly traded company; the company's stock symbol is BWAY.

What is BrainsWay's official website and social media links?

Minus sign iconPlus sign icon
BrainsWay's official website is brainsway.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does BrainsWay generate?

Minus sign iconPlus sign icon
As of August 2026, BrainsWay's annual revenue is estimated to be $25M - $50M.

What is BrainsWay's NAICS code?

Minus sign iconPlus sign icon
BrainsWay's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does BrainsWay have currently?

Minus sign iconPlus sign icon
As of August 2026, BrainsWay has approximately 145 employees across 3 continents, including North America, Asia and Europe. Key team members include Chief Executive Officer: H. L., Cfo: I. M. and Chief Technology Officer: G. M. Explore BrainsWay's employee directory with LeadIQ.

What industry does BrainsWay belong to?

Minus sign iconPlus sign icon
BrainsWay operates in the Medical Equipment Manufacturing industry.

What technology does BrainsWay use?

Minus sign iconPlus sign icon
BrainsWay's tech stack includes Microsoft Advertising, HubSpot Analytics, Tableau, Drupal, WooCommerce, Microsoft 365, WP Engine and Piwik.

What is BrainsWay's email format?

Minus sign iconPlus sign icon
BrainsWay's email format typically follows the pattern of First.Last@brainsway.com. Find more BrainsWay email formats with LeadIQ.

How much funding has BrainsWay raised to date?

Minus sign iconPlus sign icon
As of August 2026, BrainsWay has raised $85M in funding. The last funding round occurred on Oct 30, 2024 for $20M.

When was BrainsWay founded?

Minus sign iconPlus sign icon
BrainsWay was founded in 2003.
BrainsWay logo

BrainsWay

Medical Equipment ManufacturingMassachusetts, United States51-200 Employees

BrainsWay is a medical equipment manufacturer focused on noninvasive neurostimulation therapies for mental health disorders. Its Deep Transcranial Magnetic Stimulation platform has three FDA-cleared indications, supported by pivotal studies, for major depressive disorder (including anxious depression), obsessive-compulsive disorder, and smoking addiction. The company emphasizes building a robust clinical evidence base and expanding global awareness and access to Deep TMS.

Headquartered in Burlington, Massachusetts, with an office in Jerusalem, BrainsWay was founded in 2003 and operates as a mid-sized company. Its work centers on advancing clinical evidence and broadening access through ongoing trials across psychiatric, neurological, and addiction disorders. In June 2026, BrainsWay presented durability data from its accelerated Deep TMS program at the Clinical TMS Society Annual Meeting, reporting a remission rate exceeding 80% one year after treatment and a substantial reduction in severe functional impairment.

Section iconCompany Overview

Stock Symbol
BWAY
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2003
Employees
51-200

Section iconFunding & Financials

  • $85M

    BrainsWay has raised a total of $85M of funding over 5 rounds. Their latest funding round was raised on Oct 30, 2024 in the amount of $20M as a Post IPO Equity.

  • $25M - $50M

    BrainsWay's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.